TUSTIN, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - News), a biopharmaceutical company with a portfolio of innovative, clinical stage products for the treatment of cancer and hepatitis C virus infection, today reported new research that validates a second phospholipid drug target in Peregrine’s proprietary anti-phospholipid platform. The data indicated that the new target, known as PE (or phosphatidylethanolamine), can be specifically targeted on tumor blood vessels for anti-cancer applications, similar to the activity of PS (or phosphatidylserine), the target for Peregrine’s bavituximab program. The data were presented today by Dr. Philip Thorpe, an inventor of the anti-phospholipid technology, at the 2nd European Conference on Tumor Angiogenesis and Antiangiogenic Therapy in Munich, Germany.
